Neoleukin Therapeutics (NLTX) Insider Trading & Ownership $17.69 +0.59 (+3.45%) As of 02/28/2025 Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends Neoleukin Therapeutics (NASDAQ:NLTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage1.58%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$1.31 MNumber OfInsiders Selling(Last 3 Years)2Amount OfInsider Selling(Last 3 Years)$11,770.80 Get NLTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Neoleukin Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address NLTX Insider Buying and Selling by Quarter Neoleukin Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/17/2023Bros. Advisors Lp BakerDirectorBuy8,347$13.80$115,188.60 8/15/2023Bros. Advisors Lp BakerDirectorBuy94,440$12.60$1,189,944.00 8/11/2023Sean Michael SmithCFOSell66$12.40$818.40 4/3/2023Priti PatelInsiderSell188$13.80$2,594.40 8/10/2022Sean Michael SmithInsiderSell82$19.80$1,623.60 5/2/2022Priti PatelInsiderSell276$24.40$6,734.40 (Data available from 1/1/2013 forward) NLTX Insider Trading Activity - Frequently Asked Questions Who is on Neoleukin Therapeutics's Insider Roster? The list of insiders at Neoleukin Therapeutics includes Bros. Advisors Lp Baker, Priti Patel, and Sean Michael Smith. Learn more on insiders at NLTX. What percentage of Neoleukin Therapeutics stock is owned by insiders? 1.58% of Neoleukin Therapeutics stock is owned by insiders. Learn more on NLTX's insider holdings. Which Neoleukin Therapeutics insiders have been buying company stock? The following insider purchased NLTX shares in the last 24 months: Bros. Advisors Lp Baker ($1,305,132.60). How much insider buying is happening at Neoleukin Therapeutics? Insiders have purchased a total of 102,787 NLTX shares in the last 24 months for a total of $1,305,132.60 bought. Which Neoleukin Therapeutics insiders have been selling company stock? The following insiders have sold NLTX shares in the last 24 months: Priti Patel ($2,594.40), and Sean Michael Smith ($818.40). How much insider selling is happening at Neoleukin Therapeutics? Insiders have sold a total of 254 Neoleukin Therapeutics shares in the last 24 months for a total of $3,412.80 sold. Neoleukin Therapeutics Key ExecutivesMs. Donna M. Cochener-Metcalfe J.D. (Age 48)General Counsel, Interim CEO & Corporate Secretary Compensation: $403.75kDr. David Baker M.D.Ph.D., Co-FounderMr. Sean Michael Smith (Age 37)Interim Chief Financial Officer More Insider Trading Tools from MarketBeat Related Companies Praxis Precision Medicines Insider Selling Nuvation Bio Insider Selling LENZ Therapeutics Insider Selling CorMedix Insider Selling Dianthus Therapeutics Insider Selling Tyra Biosciences Insider Selling Kura Oncology Insider Selling Xeris Biopharma Insider Selling ORIC Pharmaceuticals Insider Selling Sana Biotechnology Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:NLTX) was last updated on 3/4/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
